Maze therapeutics reports fourth quarter and full-year 2024 financial results and recent highlights

Mze829 phase 2 horizon trial enrolling patients with apol1 kidney disease (akd); initial data expected in q1 2026 mze782 phase 1 healthy volunteer trial ongoing; initial data expected in h2 2025 raised $140 million in gross proceeds in upsized ipo in february 2025, providing expected cash runway into h2 2027 south san francisco, calif., march 31, 2025 (globe newswire) -- maze therapeutics, inc. (nasdaq: maze), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, cardiovascular and metabolic diseases, today reported financial results for the fourth quarter and year ended december 31, 2024, highlighted recent progress and reiterated upcoming milestones.
MAZE Ratings Summary
MAZE Quant Ranking